NASDAQ:SHPG - Shire Stock Price, News & Analysis

Today's Range N/A
50-Day Range
$179.20
MA: $179.20
$179.20
52-Week Range N/A
VolumeN/A
Average Volume2.21 million shs
Market Capitalization$54.71 billion
P/E Ratio11.83
Dividend Yield0.19%
Beta0.87
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SHPG
CUSIPN/A
Phone353-1609-6000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$15.16 billion
Book Value$119.43 per share

Profitability

Net Income$4.27 billion

Miscellaneous

EmployeesN/A
Market Cap$54.71 billion
Next Earnings DateN/A
OptionableOptionable

Receive SHPG News and Ratings via Email

Sign-up to receive the latest news and ratings for SHPG and its competitors with MarketBeat's FREE daily newsletter.


Shire (NASDAQ:SHPG) Frequently Asked Questions

What is Shire's stock symbol?

Shire trades on the NASDAQ under the ticker symbol "SHPG."

How were Shire's earnings last quarter?

Shire PLC (NASDAQ:SHPG) posted its earnings results on Thursday, April, 26th. The biopharmaceutical company reported $3.86 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $3.58 by $0.28. The biopharmaceutical company had revenue of $3.77 billion for the quarter. Shire had a net margin of 30.63% and a return on equity of 12.70%. Shire's revenue was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.63 EPS. View Shire's Earnings History.

What price target have analysts set for SHPG?

8 equities research analysts have issued twelve-month target prices for Shire's shares. Their forecasts range from $195.00 to $222.00. On average, they anticipate Shire's stock price to reach $204.3333 in the next year. View Analyst Price Targets for Shire.

What is the consensus analysts' recommendation for Shire?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Shire in the last year. There are currently 5 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Shire.

Has Shire been receiving favorable news coverage?

News coverage about SHPG stock has been trending positive recently, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Shire earned a media sentiment score of 2.5 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the near future. View News Stories for Shire.

Who are some of Shire's key competitors?

What other stocks do shareholders of Shire own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Shire investors own include Gilead Sciences (GILD), Celgene (CELG), Intel (INTC), Walt Disney (DIS), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Cisco Systems (CSCO), Netflix (NFLX) and Allergan (AGN).

Who are Shire's key executives?

Shire's management team includes the folowing people:
  • Dr. Flemming Ornskov M.P.H., MBA, M.D., MPH, CEO, MD & Exec. Director (Age 60)
  • Mr. Thomas J. W. Dittrich, CFO & Director (Age 54)
  • Gisele Dion, Chief Accounting Officer
  • Mr. Matthew Walker, Head of Technical Operations (Age 54)
  • Dr. Andreas Busch Ph.D., Head of R&D and Chief Scientific Officer (Age 55)

How do I buy shares of Shire?

Shares of SHPG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How big of a company is Shire?

Shire has a market capitalization of $0.00 and generates $15.16 billion in revenue each year. The biopharmaceutical company earns $4.27 billion in net income (profit) each year or $15.15 on an earnings per share basis. View Additional Information About Shire.

What is Shire's official website?

The official website for Shire is http://www.shire.com/.

How can I contact Shire?

Shire's mailing address is BLOCK 2 MIESIAN PLAZA 50-58 BAGGOT STREET LOWER, Dublin L2, D02. The biopharmaceutical company can be reached via phone at 353-1609-6000 or via email at [email protected]


MarketBeat Community Rating for Shire (NASDAQ SHPG)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  1,053 (Vote Outperform)
Underperform Votes:  584 (Vote Underperform)
Total Votes:  1,637
MarketBeat's community ratings are surveys of what our community members think about Shire and other stocks. Vote "Outperform" if you believe SHPG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SHPG will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel